STAT5A and ovarian carcinoma: The capacity to target NF-κB, STAT5, and Bcl-2/Bcl-xL pathways simultaneously, and thus maximize the suppression of Bcl-xL expression, should be of great benefit to ovarian cancer patients who have developed carboplatin resistance.